Compare NUS & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUS | IPSC |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.1M | 407.6M |
| IPO Year | 1996 | 2021 |
| Metric | NUS | IPSC |
|---|---|---|
| Price | $5.86 | $2.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 574.4K | ★ 633.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 207.80 | 91.30 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $3,176,718,000.00 | $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | $148.38 | ★ N/A |
| Revenue Growth | 48.98 | ★ 1556.76 |
| 52 Week Low | $5.62 | $0.44 |
| 52 Week High | $14.62 | $2.97 |
| Indicator | NUS | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 28.01 | 46.53 |
| Support Level | N/A | $2.15 |
| Resistance Level | $11.06 | $2.41 |
| Average True Range (ATR) | 0.29 | 0.13 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 13.03 | 41.67 |
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.